Emergent Biosolutions Revenue 2010-2022 | EBS

Emergent Biosolutions revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Emergent Biosolutions Annual Revenue
(Millions of US $)
2021 $1,793
2020 $1,555
2019 $1,106
2018 $782
2017 $561
2016 $489
2015 $489
2014 $404
2013 $313
2012 $282
2011 $273
2010 $286
2009 $235
Emergent Biosolutions Quarterly Revenue
(Millions of US $)
2022-06-30 $243
2022-03-31 $308
2021-12-31 $723
2021-09-30 $329
2021-06-30 $398
2021-03-31 $343
2020-12-31 $583
2020-09-30 $385
2020-06-30 $395
2020-03-31 $193
2019-12-31 $360
2019-09-30 $312
2019-06-30 $243
2019-03-31 $191
2018-12-31 $271
2018-09-30 $174
2018-06-30 $220
2018-03-31 $118
2017-12-31 $194
2017-09-30 $149
2017-06-30 $101
2017-03-31 $117
2016-12-31 $152
2016-09-30 $143
2016-06-30 $91
2016-03-31 $103
2015-12-31 $141
2015-09-30 $158
2015-06-30 $126
2015-03-31 $64
2014-12-31 $102
2014-09-30 $138
2014-06-30 $110
2014-03-31 $54
2013-12-31 $98
2013-09-30 $89
2013-06-30 $82
2013-03-31 $43
2012-12-31 $95
2012-09-30 $67
2012-06-30 $70
2012-03-31 $50
2011-12-31 $108
2011-09-30 $59
2011-06-30 $88
2011-03-31 $19
2010-12-31 $103
2010-09-30 $74
2010-06-30 $62
2010-03-31 $47
2009-12-31 $54
2009-09-30 $43
2009-06-30 $73
2009-03-31 $65
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.040B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00